BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24212482)

  • 21. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
    Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
    Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.
    Fioretos T; Strömbeck B; Sandberg T; Johansson B; Billström R; Borg A; Nilsson PG; Van Den Berghe H; Hagemeijer A; Mitelman F; Höglund M
    Blood; 1999 Jul; 94(1):225-32. PubMed ID: 10381517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.
    Nakai H; Misawa S; Toguchida J; Yandell DW; Ishizaki K
    Cancer Res; 1992 Dec; 52(23):6588-93. PubMed ID: 1423304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis.
    Guinn BA; Smith M; Padua RA; Burnett A; Mills K
    Leuk Res; 1995 Aug; 19(8):519-25. PubMed ID: 7658697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of 30 cases of chronic myeloid leukemia with non-myeloid blast crisis].
    Ge CW; Li DG; Hao YM
    Zhonghua Nei Ke Za Zhi; 1989 Dec; 28(12):731-3, 768. PubMed ID: 2636091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
    J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review.
    Gao X; Li J; Wang L; Lin J; Jin H; Xu Y; Wang N; Zhao Y; Liu D; Yu L; Wang Q
    Am J Case Rep; 2016 Oct; 17():793-798. PubMed ID: 27784881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis.
    Calderón-Cabrera C; Montero I; Morales RM; Sánchez J; Carrillo E; Caballero-Velázquez T; Prats C; Bernal R; De Blas JM; Pérez-Simón JA
    Leuk Res Rep; 2013; 2(2):79-81. PubMed ID: 24371788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
    Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
    Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myeloid leukemia in pregnancy: an absolute contraindication to neuraxial anesthesia?
    Owsiak JN; Bullough AS
    Int J Obstet Anesth; 2016 Feb; 25():85-8. PubMed ID: 26711557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
    Griner LN; Reuther GW
    Cancer Biol Ther; 2010 Nov; 10(10):979-82. PubMed ID: 21084860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic myeloid leukemia with pure erythroid leukemia blast crisis.
    Jacobs JW; Ramaswamy R; States V; Reppucci J; Oluwole OO; Mason EF; Thompson MA
    Leuk Lymphoma; 2022 Jan; 63(1):212-216. PubMed ID: 34486918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
    Pratcorona M; Abbas S; Sanders MA; Koenders JE; Kavelaars FG; Erpelinck-Verschueren CA; Zeilemakers A; Löwenberg B; Valk PJ
    Haematologica; 2012 Mar; 97(3):388-92. PubMed ID: 22058207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
    Sen S; Zhou H; Andersson BS; Cork A; Freireich EJ; Stass SA
    Cancer Genet Cytogenet; 1995 Jul; 82(1):35-40. PubMed ID: 7627932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.